文章：

如何通过目前使用的预后模型预测成熟T细胞和NK细胞淋巴瘤的预后？

How to predict the outcome in mature T and NK cell lymphoma by currently used prognostic models?

原文发布日期：2012-10-12

DOI: 10.1038/bcj.2012.23

类型: Original Article

开放获取: 是

英文摘要：

To select an appropriate prognostic model in the treatment of mature T- and natural killer (NK) -cell lymphoma (peripheral T-cell lymphoma (PTCL) and NK-/T-cell lymphoma (NKTCL)) is crucial. This study investigated the usefulness of Ann Arbor staging classification International prognostic index (IPI), prognostic index for T-cell lymphoma (PIT) and International peripheral T-cell lymphoma Project score (IPTCLP). Between 2000 and 2009, 176 patients (122 males) with PTCL and NKTCL were diagnosed and treated from a single institute in Taiwan. The correlation between complete response (CR) rate, 3-year overall survival (OS), early mortality rate and four prognostic models was analyzed. Thirty-one patients received hematopoietic stem cell transplantation (HSCT) and were analyzed separately. Three-year OS rate was 34.7%, and anaplastic large-cell lymphoma harbored better outcome than others. IPI score had the lowest Akaike information criterion value (1081.197) and was the best score in predicting OS and early mortality (P=0.009). Ann Arbor stage classification can predict CR rate more precisely (P=0.006). OS was significantly better in patients who received HSCT, even in patients with unfavorable features compared with chemotherapy alone. All prognostic models were useful to evaluate the outcome of patients with PTCL and NKTCL but IPI score did best in predicting OS in PTCL and PIT score in NKTCL. This study also supported the role of HSCT in patients with high-risk or refractory PTCL or NKTCL.

摘要翻译： 

在选择成熟T细胞和自然杀伤（NK）细胞淋巴瘤（外周T细胞淋巴瘤（PTCL）与NK/T细胞淋巴瘤（NKTCL））治疗方案时，选取合适的预后模型至关重要。本研究评估了安阿伯分期系统、国际预后指数（IPI）、T细胞淋巴瘤预后指数（PIT）及国际外周T细胞淋巴瘤项目评分（IPTCLP）的临床应用价值。2000年至2009年间，台湾某单一医疗中心共诊断并治疗了176例PTCL与NKTCL患者（男性122例）。通过分析完全缓解率、三年总生存期、早期死亡率与四种预后模型的相关性发现，其中31例接受造血干细胞移植的患者需单独分析。三年总生存率为34.7%，间变性大细胞淋巴瘤患者预后优于其他亚型。IPI评分的赤池信息量准则值最低（1081.197），在预测总生存期和早期死亡率方面表现最佳（P=0.009），而安阿伯分期系统能更精准预测完全缓解率（P=0.006）。接受造血干细胞移植的患者即使存在不良预后因素，其总生存期仍显著优于单纯化疗组。所有预后模型均适用于PTCL与NKTCL患者的预后评估，其中IPI评分对PTCL的总生存期预测最优，PIT评分则对NKTCL更具优势。本研究同时证实了造血干细胞移植在高危或难治性PTCL与NKTCL患者治疗中的重要地位。

原文链接：

How to predict the outcome in mature T and NK cell lymphoma by currently used prognostic models?